Naprosyn

An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout. .
[PubChem].

Medicinal name:
  • Naproxen 250 MG Oral Tablet [Naprosyn]
  • Naproxen 375 MG Oral Tablet [Naprosyn]
  • Naproxen 500 MG Oral Tablet [Naprosyn]
  • Naproxen 250 MG Oral Tablet

Naprosyn - Pharmacology:

The mechanism of action of naproxen, like that of other NSAIDs, is believed to be associated with the inhibition of cyclooxygenase activity. Two unique cyclooxygenases have been described in mammals. The constitutive cyclooxygenase, COX-1, synthesizes prostaglandins necessary for normal gastrointestinal and renal function. The inducible cyclooxygenase, COX-2, generates prostaglandins involved in inflammation. Inhibition of COX-1 is thought to be associated with gastrointestinal and renal toxicity while inhibition of COX-2 provides anti-inflammatory activity.

Naprosyn mini report

Naprosyn NDA
NDA - A product marketed under an approved New Drug Application
Naprosyn ANDA
ANDA - A product marketed under an approved Abbreviated New Drug Application
Naprosyn SUSPENSION
SUSPENSION
Naprosyn TABLET
TABLET
Naprosyn HUMAN PRESCRIPTION DRUG
HUMAN PRESCRIPTION DRUG
Start - Stop data
START DATA:
2016-May-20
Start - Stop data
STOP DATA
not occurred

Naprosyn for patients

Naprelan® (naproxen sodium controlled-release tablets) represents the first prescription product to offer convenient once-a-day dosing of naproxen, a medication long considered a standard in arthritis treatment. Naprosyn or naproxen sodium-based products account for nearly one in every five prescriptions written for non-steroidal anti-inflammatory drugs (NSAID) in the United States. (Naprosyn sodium, a sodium salt formulation of naproxen, provides for more rapid absorption.)

Naprelan tablets use a proprietary delivery system IPDAS™, (Intestinal Protective Drug Absorption System), a matrix of naproxen sodium with immediate and controlled-release components. Upon ingestion, and after rapid disintegration of the tablet matrix, an initial portion (approximately 30%) of the medication is released for rapid systemic absorption -- achieving onset of analgesic action within 30 minutes. In addition, a sustained-release component of microparticles provides an extended absorption phase that has wide GI dispersion, allowing gradual absorption throughout the GI tract, and prolongs therapeutic systemic levels of the drug, enabling 24-hour duration of action and once-a-day dosing.

Naprosyn has been used safely and effectively worldwide for 20 years and is one of the NSAIDs most widely used in the treatment of osteoarthritis and rheumatoid arthritis. Numerous clinical studies have demonstrated the efficacy and safety profile of naproxen. Naprelan offers the same efficacy and safety profile with the added advantage of once-a-day dosing. The most frequent complaints relate to the gastrointestinal tract. Serious GI toxicity, such as perforation, ulceration or bleeding can occur in patients treated chronically with NSAID therapy. Please consult with your physician to see if Naprelan may be right for you.

  • Naprelan® is marketed by Wyeth-Ayerst Labratories and not associated with Syntex Puerto Rico, Inc.
  • Naprosyn is a registered trademark of Syntex Puerto Rico, Inc.
  • IPDAS™ is a trademark of élan pharma ltd.
  • Naprelan® (naproxen sodium) Controlled Release Tablets
    Equivalent to 375 mg and 500 mg naproxen

Naprosyn Interactions

The use of NSAIDs in patients who are receiving ACE inhibitors may potentiate renal disease states.

In vitro studies have shown that naproxen anion, because of its affinity for protein, may displace from their binding sites other drugs which are also albumin-bound .

Theoretically, the naproxen anion itself could likewise be displaced. Short-term controlled studies failed to show that taking the drug significantly affects prothrombin times when administered to individuals on coumarin-type anticoagulants. Caution is advised nonetheless, since interactions have been seen with other nonsteroidal agents of this class. Similarly, patients receiving the drug and a hydantoin, sulfonamide or sulfonylurea should be observed for signs of toxicity to these drugs.

Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.

The natriuretic effect of furosemide has been reported to be inhibited by some drugs of this class. Inhibition of renal lithium clearance leading to increases in plasma lithium concentrations has also been reported. Naprosyn and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.

Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly.

Caution should be used if naproxen is administered concomitantly with methotrexate. Naprosyn, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.

Drug/Laboratory Test Interactions

Naprosyn may decrease platelet aggregation and prolong bleeding time. This effect should be kept in mind when bleeding times are determined. The administration of naproxen may result in increased urinary values for 17-ketogenic steroids because of an interaction between the drug and/or its metabolites with m-dinitrobenzene used in this assay. Although 17-hydroxy-corticosteroid measurements (Porter-Silber test) do not appear to be artifactually altered, it is suggested that therapy with naproxen be temporarily discontinued 72 hours before adrenal function tests are performed if the Porter-Silber test is to be used.

Naprosyn may interfere with some urinary assays of 5-hydroxy indoleacetic acid (5HIAA).

Naprosyn Contraindications

All naproxen products are contraindicated in patients who have had allergic reactions to prescription as well as to over-the-counter products containing naproxen. Anaphylactoid reactions may occur in patients without previous known exposure or hypersensitivity to aspirin, naproxen, or other NSAIDs, or in individuals with a history of angioedema, urticaria, bronchospastic reactivity (e.g. asthma), and nasal polyps. Anaphylactoid reactions, like anaphylaxis, may have a fatal outcome. Therefore, careful questioning of patients for such things as asthma, nasal polyps, urticaria, and hypotension associated with NSAIDs before starting therapy is important. In addition, if such symptoms occur during therapy, treatment with Naprelan should be discontinued.

Manufacturers name:

  • Genentech, Inc
  • A-S Medication Solutions LLC
  • Bryant Ranch Prepack

Generic name, Overdose, Half Life Naprosyn, Food Interactions, Chemical, etc..

Naprosyn see also FDA report Ashwagandha

Arthritis